睿知中国医院研究地图
候选清单

正在招募肺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 23 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 23

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心新疆医科大学附属肿瘤医院Affiliated Cancer Hospital of Xinjiang Medical University乌鲁木齐医院页面
  2. 研究中心首都医科大学附属北京胸科医院Beijing Chest Hospital北京医院页面
  3. 研究中心中日友好医院China-Japan Friendship Hospital北京医院页面
  4. 研究中心重庆大学附属肿瘤医院Chongqing University Cancer Hospital重庆医院页面
  5. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  6. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  7. 研究中心哈尔滨医科大学附属肿瘤医院Harbin Medical University Cancer Hospital哈尔滨医院页面
  8. 研究中心河南省肿瘤医院Henan Cancer Hospital郑州医院页面
  9. 研究中心湖北省肿瘤医院Hubei Cancer Hospital武汉医院页面
  10. 研究中心湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面
  11. 研究中心辽宁省肿瘤医院Liaoning Cancer Hospital & Institute沈阳医院页面
  12. 研究中心临沂市肿瘤医院Linyi Cancer Hospital临沂医院页面
  13. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  14. 研究中心南昌大学第二附属医院Second Affiliated Hospital of Nanchang University南昌医院页面
  15. 研究中心山东省肿瘤医院Shandong Cancer Hospital and Institute济南医院页面
  16. 研究中心四川省肿瘤医院Sichuan Cancer Hospital成都医院页面
  17. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  18. 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面
  19. 研究中心华中科技大学同济医学院附属协和医院Union Hospital武汉医院页面
  20. 研究中心四川大学华西医院West China Hospital成都医院页面
  21. 研究中心襄阳市中心医院Xiangyang Central Hospital襄阳医院页面
  22. 研究中心烟台毓璜顶医院Yantai Yuhuangding Hospital烟台医院页面
  23. 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06203210,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Has histologically or cytologically documented extensive-stage small cell lung cancer (ES-SCLC).

    入选标准第 3 条

  3. Has received prior therapy with only one prior platinum-based line as systemic therapy for SCLC with at least 2 cycles of therapy and a chemotherapy free-interval [CTFI] (duration from stop date of the platinum agent in 1L therapy to radiological PD) of ≥30 days.

    入选标准第 5 条

    Has received prior treatment with orlotamab, enoblituzumab, or other B7 homologue 3 (B7-H3) targeted agents, including I-DXd.

    排除标准第 1 条

  4. Has ECOG PS of less than or equal to (≤)1 within 7 days prior to Cycle 1 Day 1 (C1D1).

    入选标准第 8 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06203210,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Sign and date the informed consent form (ICF) prior to the start of any study-specific qualification procedures.
  2. Adults greater than or equal to (≥)18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.
  3. Has histologically or cytologically documented extensive-stage small cell lung cancer (ES-SCLC).
  4. The participant must provide adequate baseline tumor samples with sufficient quantity and quality of tumor tissue content.
  5. Has received prior therapy with only one prior platinum-based line as systemic therapy for SCLC with at least 2 cycles of therapy and a chemotherapy free-interval [CTFI] (duration from stop date of the platinum agent in 1L therapy to radiological PD) of ≥30 days.
  6. Has at least 1 measurable lesion according to RECIST v1.1 as assessed by the investigator.
  7. Has documentation of radiological disease progression on or after the most recent systemic therapy.
  8. Has ECOG PS of less than or equal to (≤)1 within 7 days prior to Cycle 1 Day 1 (C1D1).
  9. Participants with brain metastasis/leptomeningeal disease are eligible if protocol specified criteria are met.

排除标准:Exclusion Criteria:

  1. Has received prior treatment with orlotamab, enoblituzumab, or other B7 homologue 3 (B7-H3) targeted agents, including I-DXd.
  2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
  3. Has received any of the comparators used in this study or any topoisomerase I inhibitor.
  4. Has inadequate washout period before randomization as specified in the protocol.
  5. Has any of the following conditions within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event.
  6. Has uncontrolled or significant cardiovascular (CV) disease.
  7. Has clinically significant corneal disease.
  8. All of the following indicators of interstitial lung disease (ILD)/pneumonitis are excluded:
  9. Any history of ILD/pneumonitis irrespective of steroid use, except for a history of radiation pneumonitis that did not require steroids.
  10. Current diagnosis of ILD.
  11. Clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out. Radiographic findings may include presence of lung parenchymal fibrosis, combined fibrosis and emphysema (CPFE), and/or interstitial lung abnormalities such as reticular opacities, traction bronchiectasis, honeycombing, or extensive ground glass opacities. Screening computed tomography (CT) scans must be submitted for independent central radiology review and results before randomization.
  12. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, including, but not limited to, any underlying pulmonary disorder and potential pulmonary involvement caused by any autoimmune, connective tissue, or inflammatory disorders, prior pneumonectomy, or requirement for supplemental oxygen.

引自 ClinicalTrials.gov, NCT06203210, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06203210,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06203210